Cantor Fitzgerald Has Positive View of ABEO FY2025 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO) – Investment analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for Abeona Therapeutics in a report released on Tuesday, November 25th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings of $1.33 per share for the year, up from their prior forecast of $1.15. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. Cantor Fitzgerald also issued estimates for Abeona Therapeutics’ FY2026 earnings at ($0.36) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.17.

ABEO has been the topic of several other reports. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research report on Monday, October 13th. Weiss Ratings lowered shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Wall Street Zen cut shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Oppenheimer boosted their target price on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the company an “outperform” rating in a report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.00.

Abeona Therapeutics Price Performance

ABEO stock opened at $5.15 on Thursday. The stock has a market capitalization of $279.08 million, a price-to-earnings ratio of 7.36 and a beta of 1.45. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. Abeona Therapeutics has a 52-week low of $3.93 and a 52-week high of $7.54. The stock’s fifty day simple moving average is $5.05 and its 200-day simple moving average is $5.89.

Hedge Funds Weigh In On Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sherbrooke Park Advisers LLC purchased a new stake in shares of Abeona Therapeutics during the third quarter valued at approximately $64,000. Qube Research & Technologies Ltd grew its holdings in Abeona Therapeutics by 568.4% during the 3rd quarter. Qube Research & Technologies Ltd now owns 225,868 shares of the biopharmaceutical company’s stock valued at $1,193,000 after purchasing an additional 192,075 shares in the last quarter. Millennium Management LLC increased its stake in Abeona Therapeutics by 176.0% during the 3rd quarter. Millennium Management LLC now owns 709,349 shares of the biopharmaceutical company’s stock worth $3,745,000 after buying an additional 452,334 shares during the period. Bank of America Corp DE lifted its holdings in Abeona Therapeutics by 176.7% in the 3rd quarter. Bank of America Corp DE now owns 912,912 shares of the biopharmaceutical company’s stock worth $4,820,000 after buying an additional 583,028 shares in the last quarter. Finally, Cable Car Capital LP acquired a new position in Abeona Therapeutics in the 3rd quarter worth $3,168,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Insider Buying and Selling at Abeona Therapeutics

In related news, SVP Brendan M. O’malley sold 9,366 shares of the stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $50,482.74. Following the completion of the sale, the senior vice president directly owned 350,763 shares in the company, valued at approximately $1,890,612.57. This represents a 2.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph Walter Vazzano sold 9,035 shares of the business’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the transaction, the chief financial officer owned 453,631 shares in the company, valued at approximately $2,445,071.09. This represents a 1.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 78,612 shares of company stock valued at $410,271 in the last quarter. Company insiders own 6.90% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.